Search Results
Your search for ,sAy matches 1419 pages
Showing 701 - 750Mentorship From a Past ASCO President and Others Steers a Career to Academic Research
Breast cancer specialist Stacy L. Moulder, MD, was born and reared in Brookhaven, Mississippi, a small town southwest of the state capital of Jackson. “I was always interested in math and science, and I had a wonderful biology teacher in high school. It was when the advanced placement courses...
The Challenge of Prognostication in the Era of Immunotherapy
GUEST EDITOR Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development. Although advances in such ...
Legal Duties of Clinicians When Terminally Ill Patients With Cancer or Their Surrogates Insist on ‘Futile’ Treatment
Law and Ethics in Oncology explores the legal and ethical issues oncologists must be aware of in this era of precision medicine and changing health-care policy, both to protect patients’ rights and to safeguard against potential legal jeopardy. For years, ASCO and other medical societies have...
European Study Shows Double Transplant Improves Survival in Myeloma
FOR NEWLY DIAGNOSED patients with multiple myeloma considered to be at high risk of disease progression, double autologous stem cell transplantation (ASCT) significantly prolongs progression-free and overall survival, vs single transplant, according to the phase III EMN02/HO95 study. The findings...
Adjuvant Chemotherapy for Upper Tract Urothelial Cancer
ADJUVANT CHEMOTHERAPY achieved robust improvements in disease-free survival and metastasis-free survival compared with surveillance in the phase III POUT study of patients with upper tract urothelial cancer.1 Further, there was an early trend toward improved overall survival with adjuvant...
Investigational Genomic Tool Identifies Consensus Molecular Subtype of Colon Tumor and May Predict Risk of Recurrence
AN INVESTIGATIONAL TOOL called ColotypeR classifies colon cancers by molecular subtype and creates a subtype-specific risk of recurrence, according to research. Developers of the tool say it will be able to guide treatment decisions. Colon cancer is highly heterogeneous in prognosis and response to ...
Advancing Cancer Research in Challenging Times
ON OCTOBER 17, 2017, Norman E. Sharpless, MD, became the 15th Director of the National Cancer Institute (NCI), succeeding Harold E. Varmus, MD, who stepped down as Director of the agency in March 2015, and replacing Douglas R. Lowy, MD, who had served as Acting Director for 2 years. The...
Why Palliative Care Isn’t Just for Older Patients With Cancer
It is well established that adolescents and young adults (AYAs) with cancer—defined by the National Cancer Institute as those between the ages of 15 and 39 years—have not reaped a comparable survival benefit as either younger or older adult cancer survivors over the past 4 decades, despite...
EXPERT POINT OF VIEW: Robert Brodsky, MD
“THE RESULTS of these two trials are more similar than different. I think the best conclusion would be that we now have two trials with consistent results and can probably, in most cases, replace low–molecular-weight heparin with direct oral anticoagulants,” said Dr. Raskob, lead investigator of...
ASCO Data-Sharing Initiatives Support Innovative Cancer Research
At the heart of every ASCO program—every clinical practice guideline, every policy statement, every scientific meeting—is evidence. What do the data say? Evidence informs decision-making across the spectrum of cancer care, from the question a bench researcher will investigate to the treatment a...
NCCN Summit Explores Survivorship Issues for Patients and Clinicians
When Yelak Biru was diagnosed with multiple myeloma in 1995, he and his physicians had one main posttreatment goal: to detect and treat any relapse early and to prolong survival as long as possible with the limited drugs available. Then, in the early 2000s, came newer treatments. Myeloma survival...
Combined Medical and Psychological Approach May Help Couples Reclaim Intimacy After Prostate Cancer Treatment
“To what extent do treatments for prostate cancer impact sexual functioning? To a great extent,” Christian Nelson, PhD, Chief, Psychiatry Service, Memorial Sloan Kettering Cancer Center, New York, told participants at the 11th Annual Oncofertility Consortium Conference in Chicago.1 Most men with...
EXPERT POINT OF VIEW: Brian M. Wolpin, MD, MPH
Invited discussant Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute in Boston, said the results of the LAPACT trial will be useful as an aid to patient counseling as well as in designing and interpreting future studies. However, he added, they are not “practice-changing,” as nanoparticle...
EXPERT POINT OF VIEW: Eric P. Winer, MD, FASCO; Heikki Joensuu, MD; and Julie Gralow, MD, FASCO
IN INTERVIEWS with The ASCO Post and in discussions held during the meeting, several breast cancer experts weighed in on the findings of GeparSepto and CALGB 40502. Eric P. Winer, MD, FASCO, Chief of the Division of Women’s Cancers and the Thompson Senior Investigator in Breast Cancer Research at ...
EXPERT POINT OF VIEW: Julie Gralow, MD, FASCO
JULIE GRALOW, MD, FASCO, Director of Breast Medical Oncology for the Seattle Cancer Care Alliance and Professor of Medical Oncology at the University of Washington School of Medicine, commented on the findings of the SUCCESS A trial in an interview with The ASCO Post. The Oxford meta-analysis...
Precision Medicine: Hope or Hype?
ALTHOUGH PRECISION medicine may be a recent discovery in some fields, it is an old story in the field of breast cancer, and one that has been exceptionally important in terms of managing the disease, according to George Sledge, MD, FASCO, Professor of Medicine and Medical Oncologist at the...
Steep Decline in Chemotherapy Use for Early-Stage Breast Cancer
The use of chemotherapy to treat women with early-stage breast cancer “declined markedly over time,” according to analysis of data from 2,926 women between the ages of 20 and 79. The trends documented “are remarkable for their steepness of decline, independent of clinical factors and despite no...
I’m Not a Victim of Cancer
What I thought after feeling a large, hard lump—similar to the feel of a granola bar—in my left breast was that I probably pulled a muscle while playing with my two young children, ages 7 and 5. Cancer never entered my mind until I asked my husband to feel the lump, and he immediately said, with...
The Roller Coaster
The following essay by Shaker R. Dakhil, MD, FACP, is adapted, with permission, from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and...
For Holly G. Prigerson, PhD, Psychosocial Issues Are at the Heart of End-of-Life Cancer Care
Holly G. Prigerson, PhD, Co-Director of the Weill Cornell Medicine’s Center for Research on End-of-Life Care, was born in Maimonides Hospital in Brooklyn, where her father had been a resident. Her family moved to Long Island, first living in Islip, where Dr. Prigerson’s father practiced medicine...
CAR T-Cell Immunotherapy Named Advance of the Year in ASCO’s Clinical Cancer Advances 2018
A new and unique new way to treat cancer—chimeric antigen receptor (CAR) T-cell therapy—is poised to transform the outlook for children and adults with certain otherwise incurable cancers. ASCO named this type of adoptive-cell immunotherapy the Advance of the Year in its annual...
Against All Odds
The days leading up to our daughter Emily’s diagnosis of acute lymphoblastic leukemia (ALL) on May 28, 2010, when she was just 5, offered few clues about the terrifying, life-and-death months and years we were about to experience. She was happy and seemingly healthy, literally until the day before...
Pomegranates and Other Polyphenols: New Evidence to Share With Prostate Cancer Patients
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Channing Paller, MD, explores the role of pomegranate- and grape-based...
NSABP B-47: No Benefit for Adjuvant Trastuzumab in HER2-Low Breast Cancer
For more than a decade, breast cancer experts have wondered whether women with low levels of HER2 might derive some benefit from trastuzumab (Herceptin), based on signals seen in earlier trastuzumab trials. Most notably, in the landmark National Surgical Adjuvant Breast and Bowel Project (NSABP) ...
Celebrating the Life of Jimmie Holland, MD
The oncology community mourns the sudden passing of Jimmie C. Holland, MD, who died on December 24, 2017, at the age of 89. Dr. Holland’s achievements over her 40-year career are legend. They include the founding of the subspecialty of psycho-oncology, the establishment of a full-time Psychiatry...
Study Finds Gene-Expression Profile Testing for Breast Cancer Less Cost-Effective in Real-World Practice
The most commonly used gene expression profile test used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers led by scientists from Georgetown Lombardi Comprehensive Cancer Center. Their study, published by Chandler et al in the Journal...
New Cancer Model Shows Genomic Link Between DCIS and IDC Breast Cancer Types
A new genetic-based model may explain how ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer, say researchers at The University of Texas MD Anderson Cancer Center. The study provides new insight into how DCIS leads to invasive ductal carcinoma (IDC) and provides a clearer...
Treatment With Carfilzomib May Lead to Cardiovascular Toxicity in Patients With Multiple Myeloma
The proteasome inhibitor carfilzomib (Kyprolis) has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy may come with the risk of cardiovascular problems in a higher than expected...
Assuming the Role of NCI Director: Working to Accelerate Progress
I’m not sure anything can prepare a person to become director of the National Cancer Institute (NCI), but I can honestly say that I am humbled to have been appointed to this position and am excited to have this unique opportunity. As many of you may know, I come to NCI from the University of...
The Puzzle Table
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Dose-Dense Chemotherapy in Early Breast Cancer: A ‘Win-Win’ Treatment Approach
INCREASING THE DOSE density of chemotherapy lowers the risk of recurrence and breast cancer death by about 15% in women with early breast cancer, according to a large, meticulously conducted meta-analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).1 The trials included in...
Front-Line Brentuximab Plus AVD vs Standard ABVD in Advanced Hodgkin Lymphoma
FRONT-LINE TREATMENT of advanced Hodgkin lymphoma with brentuximab vedotin (Adcetris) plus doxorubicin/ vinblastine/dacarbazine (A+AVD) achieved superior outcomes compared with the standard four-drug regimen of doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD). The substitution of brentuximab...
Future Directions for CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy burst upon the scene as an innovative approach to the treatment of hematologic malignancies, mainly for patients who have exhausted all other treatment options. Recently two CAR T-cell products were approved by the U.S. Food and Drug Administration...
Highlights From the Conquer Cancer Foundation’s Third Annual Career Development Retreat
The Conquer Cancer Foundation of ASCO is committed to supporting the research and career development of young researchers through its Grants & Awards Program. In October 2017, Conquer Cancer hosted its third Scientific and Career Development Retreat at ASCO Headquarters in Alexandria,...
Launching Harmonized NCCN Guidelines for Sub-Saharan Africa
Cancer care in Sub-Saharan Africa, as in other low-resource settings, can be a challenge: The right medications and equipment may be in short supply, maintaining equipment can be a problem, basic chemotherapy drugs may be unaffordable, and patients may not see doctors until the cancer is advanced....
A Vivid Look Back, a Cogent Look Forward
Cancer memoirs come in a variety of literary styles and voices. Not surprisingly, the most poignant cancer memoirs are by those who are writing, in essence, their final words before departing this earth. The most widely read of that variety has been the beautifully written best seller When Breath...
Helping Oncologists to Become Better Communicators With Their Patients
Timothy Gilligan, MD, FASCO, Co-Chair of ASCO’s Expert Panel on Patient-Physician Communications Guideline and Vice-Chair for Education and Associate Professor of Medicine at the Cleveland Clinic Taussig Cancer Institute, spends half of his professional time treating patients with urologic...
ASCO Releases Guideline to Help Oncologists Improve Communication With Patients—and Their Own Well-Being
In September 2017, ASCO published a new guideline in the Journal of Clinical Oncology that outlines best practices for communicating effectively with patients and their family members.1 The guideline is the result of recommendations from a multidisciplinary panel of experts in a number of fields,...
Addressing Disparities in Use of Lung Cancer Screening With Community Outreach
African Americans and members of other communities of lower socioeconomic status have higher burdens of lung cancer mortality. Therefore, targeting underserved patient populations with lung cancer screening is of the utmost importance, according to Christopher Lathan, MD, MS, MPH, a medical...
Tackling the High Cost of Cancer Care
AT THE 2017 ASCO ANNUAL MEETING, the leaders of the newly formed Value in Cancer Care Consortium (vi3c; vi3c.org) met to discuss the group’s plan to study how to improve the affordability of cancer drugs and make them more accessible to patients. The goal of the Value in Cancer Care Consortium is...
The Man in the Vest
It had been an uneventful Sunday morning, and I was writing my final note for the day, hopeful to make a stealth exit and perhaps join my family at church. But as I closed the chart and looked up, I saw Ruthie, my oncology fellow, approaching with a grim expression. “I just left the room of a...
Gauging the Impact of Weight Loss Intervention on Breast Cancer Outcomes
“Growing research suggests that body weight is not only related to the risk of developing malignancy, but also prognosis after diagnosis, especially in breast cancer,” said Jennifer A. Ligibel, MD, of Dana-Farber Cancer Institute and Harvard Medical School, at the 19th Annual Lynn Sage Breast...
ASCO Survey Reveals Concerning Trends in Americans’ Knowledge About Cancer Risks and Impact of Costs on Compliance
Although most Americans, 78%, recognize that smoking is a major risk factor for cancer, just 31% say obesity—the second-leading preventable cause of cancer after smoking—is a risk factor for the disease, according to the results of ASCO’s National Cancer Opinion Survey, which polled over 4,000...
A Revolutionary Technology Offers Hope and Ethical Concern
Aldous Huxley’s classic 1932 dystopian novel Brave New World pictures an eerie future where humans are genetically bred, altered to create worthy citizens. Welcome back to the future. First there was the astounding feat of sequencing the entire human genome; now, thanks to a revolutionary...
Early Study Suggests Potential Role of Paclitaxel in Peripheral Neuropathy and Possible Preventive Measures
In discovering how certain chemotherapy drugs cause peripheral neuropathy, researchers at Dana-Farber Cancer Institute have found a potential approach to preventing this common and troublesome side effect of cancer treatment. Their findings were published by Pease-Raissi et al in Neuron. The...
Adjuvant BRAF/MEK Inhibition Improves Survival in Resectable Melanoma
FOR PATIENTS with locally advanced, resectable melanoma harboring BRAF mutations, adjuvant treatment with BRAF/ MEK inhibition significantly improves overall survival, results of the COMBI-AD trial have shown. The study was presented at the European Society for Medical Oncology (ESMO) 2017...
Expert Point of View: Brian G. Czito, MD, and Phuoc T. Tran, MD, PhD
“THESE PRELIMINARY STUDY RESULTS suggest that combining these modalities [immunotherapy and radiation therapy] can halt tumor growth in 30% to 57% of patients, with the radiation-induced tumor response acting as a sort of vaccine in combination with immunotherapy. This cutting-edge strategy...
Could the Rising Rates of Colorectal Cancer in AYAs Be Linked to HPV Infection?
TWO STUDIES published this year examining the incidence of colorectal cancer in adolescents and young adults (AYAs) show an undeniable and sobering trend: Colorectal cancer rates are increasing in this age group, and younger people are dying of the cancer at slightly higher rates than in previous...
Cancers Associated With Overweight and Obesity Make Up 40% of Cancers Diagnosed in the United States
Overweight and obesity are associated with increased risk of 13 types of cancer—and these cancers account for about 40% of all cancers diagnosed in the United States in 2014—according to the latest Vital Signs report by the Centers for Disease Control and Prevention (CDC). Overall, the...
Cancer Has Plagued My Family
My father, who was a physician, taught me at an early age to pay attention to any changes in my body. His advice has stood me in good stead for more than 83 years and probably saved my life more than once. In 1984, just before I turned 50, something was bothering me about my right breast. I could...
